Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Bevacizumab rechallenge after first line maintenance bevacizumab.

Konstantinopoulos PA, Berlin ST, Campos SM, Matulonis UA, Cannistra SA. Bevacizumab rechallenge after first line maintenance bevacizumab. Gynecol Oncol. 2012 May; 125(2):510-1.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.